Study allays fears over long-term alendronate

LONG-TERM users of the osteoporosis drug alendronate are at no greater risk of developing atypical femur fractures over at least 10 years of treatment, a Danish study shows.

The finding comes as fears of bisphosphonate side effects kindled in the mainstream media are leading many osteoporosis patients to abandon their treatment.

Researchers found the incidence of atypical femur